# K221624: Avenda Health AI Prostate Cancer Planning Software

- Pathway: 510(k) (Traditional)
- Applicant: Avenda Health, Inc.
- Decided: Nov 22, 2022 after 169 days
- Product code: POK (Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer)
- Device class: 2
- Regulation: 21 CFR 892.2060
- Recalls of this device: none
- Data: FDA decisions to Oct 25, 2026; recalls to Oct 12, 2026

## Lineage
Longest line of descent: 1 generation back to DEN170022 (2017). 1 ancestor in all.
No later device cites it as a predicate yet.
0 of 2 devices in its family (counting itself) have a Class I recall.

## Predicates on the family tree (from the FDA summary)
- DEN170022: QuantX, Quantitative Insights, Inc. (2017) Summary page 5.

## Indications for use
The Avenda Health AI Prostate Cancer Planning Software is an artificial intelligence (AI)-based decision support software, indicated as an adjunct to the review of magnetic resonance (MR) prostate images and biopsy findings in the prostate oncological workflow. The Avenda Health AI Prostate Cancer Planning Software is designed to support the prostate oncological workflow by helping the user with the segmentation of MR image features, including the prostate; in the evaluation, quantification, and documentation of lesions; and in pre-planning for diagnostic and interventional procedures such as biopsy and/or soft tissue ablation. The device is intended to be used by physicians trained in the oncological workflow in a clinical setting for planning and guidance for clinical, interventional, diagnostic, and/or treatment procedures of the prostate. The Avenda Health AI Prostate Cancer Planning Software’s lesion characterization functions are intended for use on patients with a pathology-confirmed Gleason Grade Group (GGG) ≥ 2 lesion and for whom corresponding biopsy coordinate information have been uploaded. These functions are indicated for the evaluation of the extent of known disease. Extent of known disease refers to the boundary of a pathology confirmed lesion of GGG ≥ 2 for a particular patient. Specifically, using prostate MR images, biopsy, pathology, and clinical data, the device creates and displays a cancer map that assigns a probability to each voxel within the prostate, indicating its probability for containing clinically significant prostate cancer (csPCa, defined as GGG ≥ 2 ). A user selects a threshold for the cancer map to create a boundary of the lesion. The lesion boundary is assigned an Encapsulation Confidence Score indicating the confidence that all csPCa is encapsulated within the boundary. The Encapsulation Confidence Score is from a lookup table generated by a database of cases with known ground-truth. When interpreted by a trained physician, this information may be useful in supporting lesion characterization and subsequent patient management. The Avenda Health AI Prostate Planning Software may also be used as a medical image application, for the viewing, manipulation, 3D-visualization, and comparison of MR prostate images. The images can be viewed in a number of output formats including volume rendering. It enables visualization of information that would otherwise have to be visually compared disjointedly.

Source page: https://510kreport.com/device/K221624
Methodology: https://510kreport.com/methodology